461 related articles for article (PubMed ID: 31430334)
21. Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.
Kaplow J; Vandijck M; Gray J; Kanekiyo M; Huyck E; Traynham CJ; Esquivel R; Fagan AM; Luthman J
Alzheimers Dement; 2020 Jan; 16(1):144-152. PubMed ID: 31914216
[TBL] [Abstract][Full Text] [Related]
22. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O;
Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982
[TBL] [Abstract][Full Text] [Related]
23. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
24. Concordance between brain
Rubí S; Noguera A; Tarongí S; Oporto M; García A; Vico H; Espino A; Picado MJ; Mas A; Peña C; Amer G
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):3-8. PubMed ID: 28645685
[TBL] [Abstract][Full Text] [Related]
25. Associations between [
La Joie R; Bejanin A; Fagan AM; Ayakta N; Baker SL; Bourakova V; Boxer AL; Cha J; Karydas A; Jerome G; Maass A; Mensing A; Miller ZA; O'Neil JP; Pham J; Rosen HJ; Tsai R; Visani AV; Miller BL; Jagust WJ; Rabinovici GD
Neurology; 2018 Jan; 90(4):e282-e290. PubMed ID: 29282337
[TBL] [Abstract][Full Text] [Related]
26. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding.
Tolboom N; van der Flier WM; Yaqub M; Boellaard R; Verwey NA; Blankenstein MA; Windhorst AD; Scheltens P; Lammertsma AA; van Berckel BN
J Nucl Med; 2009 Sep; 50(9):1464-70. PubMed ID: 19690025
[TBL] [Abstract][Full Text] [Related]
27. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
28. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
29. Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
Reimand J; Groot C; Teunissen CE; Windhorst AD; Boellaard R; Barkhof F; Nazarenko S; van der Flier WM; van Berckel BNM; Scheltens P; Ossenkoppele R; Bouwman F
J Alzheimers Dis; 2020; 73(2):559-569. PubMed ID: 31796674
[TBL] [Abstract][Full Text] [Related]
30. The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort.
Amft M; Ortner M; Eichenlaub U; Goldhardt O; Diehl-Schmid J; Hedderich DM; Yakushev I; Grimmer T
Alzheimers Res Ther; 2022 Apr; 14(1):60. PubMed ID: 35473631
[TBL] [Abstract][Full Text] [Related]
31. Reference measurement procedure for CSF amyloid beta (Aβ)
Pannee J; Portelius E; Minthon L; Gobom J; Andreasson U; Zetterberg H; Hansson O; Blennow K
J Neurochem; 2016 Nov; 139(4):651-658. PubMed ID: 27579672
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
[TBL] [Abstract][Full Text] [Related]
33. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.
Salvadó G; Molinuevo JL; Brugulat-Serrat A; Falcon C; Grau-Rivera O; Suárez-Calvet M; Pavia J; Niñerola-Baizán A; Perissinotti A; Lomeña F; Minguillon C; Fauria K; Zetterberg H; Blennow K; Gispert JD;
Alzheimers Res Ther; 2019 Mar; 11(1):27. PubMed ID: 30902090
[TBL] [Abstract][Full Text] [Related]
34. Correlation of florbetaben PET imaging and the amyloid peptide Aß42 in cerebrospinal fluid.
Schipke CG; Koglin N; Bullich S; Joachim LK; Haas B; Seibyl J; Barthel H; Sabri O; Peters O
Psychiatry Res Neuroimaging; 2017 Jul; 265():98-101. PubMed ID: 28024844
[TBL] [Abstract][Full Text] [Related]
35. Clinical impact of [
Leuzy A; Savitcheva I; Chiotis K; Lilja J; Andersen P; Bogdanovic N; Jelic V; Nordberg A
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1276-1286. PubMed ID: 30915522
[TBL] [Abstract][Full Text] [Related]
36. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
[TBL] [Abstract][Full Text] [Related]
37. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
[TBL] [Abstract][Full Text] [Related]
38. Correlation Between Amyloid PET Imaging and Discordant Cerebrospinal Fluid Biomarkers Results in Patients with Suspected Alzheimer's Disease.
Lojo-Ramírez JA; Guerra-Gómez M; Marín-Cabañas AM; Fernández-Rodríguez P; Bernal Sánchez-Arjona M; Franco-Macías E; García-Solís D
J Alzheimers Dis; 2024; 97(1):447-458. PubMed ID: 38143353
[TBL] [Abstract][Full Text] [Related]
39. Challenges in Alzheimer's Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences.
Lombardi G; Pupi A; Bessi V; Polito C; Padiglioni S; Ferrari C; Lucidi G; Berti V; De Cristofaro MT; Piaceri I; Bagnoli S; Nacmias B; Sorbi S
J Alzheimers Dis; 2020; 77(1):203-217. PubMed ID: 32716357
[TBL] [Abstract][Full Text] [Related]
40. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M
J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
